Health ❯Healthcare

Diabetes

Investments Patient Care Weight Management Ophthalmology Drug Approval Diabetes Treatments Dietary Interventions Patient Outcomes Obesity Treatment Medical Research

Eli Lilly’s Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End

Phase 3 data recorded an average 7.9% weight loss alongside blood sugar reductions up to 1.6% with side effects akin to injectables.

Stories older than 24h

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy

Mounjaro Delivers Rapid Weight Loss as UK Health Officials Warn of Serious Risks

Skin barrier test could reshape diabetic foot ulcer closure standards

FDA Chief Criticizes Medical Establishment, Advocates Lifestyle Changes for Health

First Human Trial of Type 1 Diabetes Immunotherapy Underway in Australia

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

WeightWatchers Prepares for Bankruptcy as Weight Loss Drug Demand Surges

Eli Lilly's Mounjaro Launches in India, Targeting Obesity and Diabetes

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials